Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03739606
Title Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

hematologic cancer

Hodgkin's lymphoma

chronic myeloid leukemia

acute leukemia

hairy cell leukemia

acute lymphoblastic leukemia

Therapies

Flotetuzumab

Age Groups: adult | child | senior
Covered Countries


No variant requirements are available.